Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Can Lubricating Joints Prevent Osteoarthritis?

Deepak Rao MD, PhD  |  June 13, 2013

There are frustratingly few therapeutic options for osteoarthritis, and our ability to slow or prevent cartilage damage is limited. A recent article published by Ruan and colleagues in Science Translational Medicine highlights the potential of one molecule, proteoglycan 4 (Prg4), also known as lubricin, to potentially slow the process of cartilage destruction in osteoarthritis.1
Lubricin is a large protein produced by chondrocytes and synoviocytes that helps protect joints by lubricating articular surfaces and dissipating strain.2 Mutations in the gene encoding lubricin cause a syndrome known as camptodactyly-arthropathy-coxa vara-pericarditis, which is characterized by premature joint damage.3 It has been previously shown in a rat model of posttraumatic osteoarthritis that intraarticular injection of Prg4 once or thrice weekly slowed loss of articular cartilage and accumulation of joint damage.4

In the current report, Ruan et al used two strategies to overexpress lubricin in the joints of mice, and then evaluated the effect of increased Prg4 expression in mouse models of osteoarthritis. First, the authors examined mice genetically engineered to secrete high levels of lubricin from chondrocytes. These mice have a normal size and stature; however, as they age, mice with increased production of Prg4 accumulated less age-related cartilage damage compared to wild-type control mice. In a model of posttraumatic osteoarthritis caused by transection of the anterior cruciate ligament, lubricin-overexpressing mice lost cartilage more slowly and maintained better function than wild-type control mice.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The authors then asked whether boosting lubricin production after an injury might also protect joints from posttraumatic cartilage loss. To do this, they injected into mouse joints an adenovirus-encoding lubricin, which infects synoviocytes and chondrocytes and stimulates increased lubricin production. Remarkably, when mice are subjected to ACL transection and then injected with the lubricin-encoding virus two weeks later, enhanced expression of lubricin reduces cartilage destruction assessed at the end of eight weeks. The mechanism by which increased lubricin expression protects joints may involve enhanced boundary lubrication or strain dissipation. In addition, through mRNA expression analyses, the authors suggest a mechanism by which lubricin may inhibit signaling pathways that drive chondrocyte hypertrophy and inflammation. The compelling in vivo results, including the ability to protect joints by treating even after the traumatic event, provide further support for the potential of lubricin supplementation to slow joint damage in clinical osteoarthritis. In the future, we may see intraarticular lubricin supplementation, or maybe even viral-induced lubricin overexpression, as a potential therapeutic option in osteoarthritis.


Dr. Rao is a rheumatology fellow at Brigham and Women’s Hospital in Boston.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Ruan MZ, Erez A, Guse K, et al. Proteoglycan 4 expression protects against the development of osteoarthritis. Sci Transl Med. 2013;5:176ra34.
  2. Jay GD, Torres JR, Warman ML, Laderer MC, Breuer KS. The role of lubricin in the mechanical behavior of synovial fluid. Proc Natl Acad Sci USA. 2007;104:6194-6199.
  3. Marcelino J, Carpten JD, Suwairi WM, et al. CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Nat Genet. 1999;23:319-322.
  4. Flannery CR, Zollner R, Corcoran C, et al. Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum. 2009;60:840-847. 

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:cartilagejointsOsteoarthritis

Related Articles

    New Therapeutics for Osteoarthritis May Be in Sight

    April 1, 2015

    Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

    Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery

    November 28, 2018

    Tom Appleton, MD, PhD CHICAGO—Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints. Post-traumatic osteoarthritis (OA) may account for…

    2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy

    April 14, 2016

    Nanotubes can penetrate the dense cartilage extracellular matrix, translocate into the cytoplasm of the chondrocytes and deliver mASO, and have staying power. Forance/shutterstock.com SAN FRANCISCO—Penetrating the dense extracellular matrix of cartilage is a challenge for administering osteoarthritis drugs, but an answer might lie in the matrix itself—in particular, its electrical charge, researchers reported at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences